investor update ..march 2007

Ventracor has made great progress in the last few months, and we are poised for major expansion as the year develops.
Key milestones achieved include:

* CE Mark approval to market in Europe ? December 2006
* FDA grants conditional approval for Destination Therapy (DT) Clinical Trial protocol ? December 2006
* Feasibility Study ? 10 patient enrolment achieved ? January 2007
* FDA agreement to extension of Feasibility Trial
* FDA agrees to US Bridge to Transplant (BTT) Pivotal Trial protocol, unconditional approval granted ? January 2007
* Australian Government approval of Commercial Ready Grant ? January 2007


A full copy of the document sent to all shareholders is attached. It is also available at


http://www.ventracor.com/uploads/news/VCR_..._March_2007.pdf